A case report has described the use of CD19-CAR-T cells with membrane-bound IL-15 for B-ALL (following CD19- and CD22-CAR-T cell therapy failure) (89), demonstrating such IL-15-expressing CAR-T cells can be applied to hematological malignancies. The gene discussed is CD22; the disease is acute lymphoblastic leukemia.